Ab
Abbisko Therapeutics
Shanghai CNFounded 2016100 employees
Private CapbiotechPrivateOncology
Platform: ALK/ROS1 TKI
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Mavuvorutinib | ABB-7872 | Phase 2/3 | 1 | C5 | GIST | ||
| Lisoderotide | ABB-6347 | Phase 2 | 1 | FLT3 | Schizophrenia | ||
| ABB-7827 | ABB-7827 | NDA/BLA | 2 | SHP2 | MDS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)